Seres Therapeutics, Inc. cotiza a 2.53 USD y tiene una capitalización bursátil de $25M. En los últimos 12 meses ha facturado $2M con un margen de flujo de caja libre del 109.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream inf…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $1.07 | $-2.08 | $-1.76 |
| Estimado | $-1.00 | $-2.18 | $-1.88 | $-1.60 |
| Sorpresa | — | +149.1% | -10.6% | -10.0% |
| Métrica | MCRB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -11910.1% | -38.6% | -11871.5% |
| Net Margin | 721.9% | -33.6% | +755.5% |
| FCF Margin | 109.6% | -13.9% | +123.5% |
| ROE | 12.9% | -40.4% | +53.3% |
| ROA | 4.1% | -32.0% | +36.1% |
| Current Ratio | 2.56 | 2.84 | -0.28 |
| Debt / Equity | — | 0.28 | — |